Tecentriq (atezolizumab) / Roche - LARVOL DELTA

Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL). (PubMed, J Hepatol) - P | "LT after Atezo-Bev is characterized by competitive RFS estimates in intermediate and advanced HCC presenting beyond transplant indications. Acute rejection seems increased but remains clinically manageable. LT should be considered after HCC response to immunotherapy."

Journal • Cardiovascular • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis • Transplant Rejection • Transplantation

MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - P1/2 | N=290 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2022 ➔ Jun 2024 | Trial primary completion date: Nov 2022 ➔ Jun 2024

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • PD-L1

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: Hoffmann-La Roche | Phase classification: P4 ➔ P3

Phase classification • Oncology

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P4 | N=1000 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology

A case of a patient with advanced HCC with Vp4 on hemodialysis who responded to a multimodality treatment including hepatic arterial infusion, radiation therapy, immunotherapy, and molecular-targeted drugs. (PubMed, Clin J Gastroenterol) - "Initial treatment consisted of hepatic arterial infusion chemotherapy with cisplatin (CDDP) as a one-shot infusion and radiotherapy targeting the main tumor and Vp4, followed by combination therapy with atezolizumab and bevacizumab (Atezo-Bev)...As second-line therapy, lenvatinib preceded by CDDP infusion (LEN-CDDP) was initiated, resulting in partial response (PR) by RECIST...Upon tumor marker elevation, third-line therapy with durvalumab and tremelimumab (Dur-Tre) was started, leading to normalization of tumor markers and sustained CR by RECIST. The patient remains alive 19 months after initiation of treatment, with preserved liver function and stable dialysis status. This case demonstrates the feasibility and potential efficacy of combining locoregional and sequential systemic therapies, including immune checkpoint inhibitors and molecular-targeted agents, in dialysis patients with advanced HCC with Vp4, a population with poor prognosis and limited evidence."

IO biomarker • Journal • Cardiovascular • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis

MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - P1/2 | N=290 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • PD-L1

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=250 | Recruiting | Sponsor: Hoffmann-La Roche | N=410 ➔ 250

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • PD-L1

Functional convergence towards short chain fatty acid metabolism shapes responsiveness to atezolizumab plus bevacizumab across Western and Eastern populations despite distinct gut microbial composition (EASL 2026) - No abstract available

Clinical • Liver Cancer • Oncology • Solid Tumor

First-Line Atezolizumab Plus Chemotherapy in Elderly Patients With Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial (IASLC-WCLC 2025) - "The IFCT-1805 ELDERLY trial assessed the addition of atezolizumab (ATZ), an ICI targeting the human programmed death-ligand 1 (PD-L1), to the current standard of care by monthly carboplatin with weekly paclitaxel CT (E Quoix et al, Lancet 2011) in elderly patients with advanced NSCLC. Conclusions : In the IFCT-1805 ELDERLY trial, despite a numerically longer OS when adding ATZ to the current standard of care CT for first line therapy of elderly patients with NSCLC, the gain was not statistically significant. However, the addition of ATZ to CT significantly improved the PFS, the ORR and the DOR regardless of PD-L1 expression."

Clinical • IO biomarker • Metastases • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • EGFR

Leveraging artificial intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: Translational analyses of AtezoTRIBE and AVETRIC trials (ESMO 2025) - P2 | "Methods Lunit SCOPE IO quantified the density of lymphocytes (LC), fibroblasts (FB), macrophages (MP), tumor (TC), endothelial (EC) and mitotic (MTC) cells in cancer area (CA) and stroma (CS) on pre-treatment H&E WSIs from pts with pMMR mCRC enrolled in AtezoTRIBE (FOLFOXIRI/bevacizumab +/- atezolizumab [atezo]) and AVETRIC (FOLFOXIRI/cetuximab/avelumab) trials...In the AVETRIC cohort, WSIs from 48 pts were analyzed; 36 (75%) cases were classified as biomarker- high , with better PFS ( P = .043) and OS ( P = .053) compared to biomarker- low ones. Conclusions Our AI-derived tumour microenvironment biomarker may help to predict benefit from ICI-based treatments in pMMR mCRC, supporting further investigations of AI-powered approaches."

Checkpoint inhibition • Clinical • IO biomarker • Colorectal Cancer • Oncology

A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis. (ASCO-GU 2026) - P2 | "The CONTACT-02 trial showed efficacy of cabozantinib combined with the PD-L1 inhibitor atezolizumab in mCRPC...Baseline characteristics: 50% (12/24) had de novo metastatic disease, 91.7% (n=22) had bone metastases, 29.2% (n=7) bone-only disease, 16.7% (n=4) visceral metastases, 66.7% (n=16) received prior chemotherapy, and 25% (n=6) prior ¹⁷⁷Lu-PSMA-617 therapy... The CANOPY trial met its interim efficacy threshold, demonstrating activity of cabozantinib plus nivolumab in mCRPC patients. The combination showed manageable toxicity. The study continues to Stage 2 enrollment to further evaluate this promising combination therapy."

Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AXL

MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - P1/2 | N=290 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Nov 2021 ➔ Nov 2022 | Trial primary completion date: Nov 2021 ➔ Nov 2022

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • PD-L1

Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase III STELLAR-303 study (ESMO 2025) - P3 | "Conclusions Zanza + atezo significantly improved OS vs rego with no new safety signals, representing a potential new treatment option for pts with previously treated mCRC. The trial continues to the final OS analysis in the nlmITT population."

Clinical • Late-breaking abstract • Metastases • P3 data • Colorectal Cancer • Gastrointestinal Cancer • Microsatellite Instability • Oncology • AXL • MSI

M24-633: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Participants with Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrialsregister.eu) - P1/2 | N=18 | Not yet recruiting | Sponsor: AbbVie Deutschland GmbH & Co. KG

Adverse events • New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. (PubMed, ESMO Open) - "MSI-like GES does not identify a population with higher sensitivity to immune checkpoint plus angiogenesis inhibition. However, responses are promising in patients with MSI tumors and, to a lesser extent, in patients without liver metastasis regardless of MSI status."

IO biomarker • Journal • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Microsatellite Instability • Oncology • Solid Tumor • MSI

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=242 | Recruiting | Sponsor: Hoffmann-La Roche | Active, not recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. (PubMed, Nature) - "At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran1 (individualized neoantigen vaccine with backbone-optimized uridine mRNA-lipoplex nanoparticles) and modified (m) FOLFIRINOX (chemotherapy) in patients with PDAC, we find that responders with vaccine-induced T cells (n = 8) have prolonged recurrence-free survival (RFS; median not reached) compared with non-responders without vaccine-induced T cells (n = 8; median RFS 13.4 months; P  =  0.007)...Thus, in PDAC, autogene cevumeran induces de novo CD8+ T cells with multiyear longevity, substantial magnitude and durable effector functions that may delay PDAC recurrence. Adjuvant mRNA-lipoplex neoantigen vaccines may thus solve a pivotal obstacle for cancer vaccination."

IO biomarker • Journal • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CD8

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial. (PubMed, Nat Commun) - P2 | "Unresectable stage III NSCLC standard treatment is chemo-radiotherapy (CT-RT) followed by immunotherapy (IO) with durvalumab...Non-resectable stage IIIA-IIIC NSCLC patients received induction ChIO (atezolizumab + carboplatin + paclitaxel, for 3 cycles), followed by concurrent CT-RT (3 cycles), and IO maintenance (atezolizumab for 16 cycles)...Grade ≥3 TRAEs occurred in 11 (28.9%) during induction, 10 (26.3%) during CT-RT, and 2 (5.3%) during maintenance. ChIO induction before CT-RT and IO maintenance showed activity and safety, warranting confirmation in larger studies."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - P1/2 | N=340 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • PD-L1

Impact of Borderline Resectable Criteria on Hepatocellular Carcinoma Treatment From the Perspective of Tumor Burden. (PubMed, World J Surg) - "Macrovascular invasion significantly impacted prognosis in patients undergoing hepatectomy, for both BR1 and BR2, whereas any of the tumor factors did not affect the prognosis of patients receiving systemic chemotherapy. Tumor burden correlated with prognosis in the entire cohort but not in chemotherapy responders, suggesting effective treatment may overcome poor prognostic indicators."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002). (PubMed, Lung Cancer) - "Carboplatin plus nab-paclitaxel with atezolizumab is a potentially feasible treatment option for advanced nonsquamous NSCLC with renal impairment."

Journal • P2 data • Chronic Kidney Disease • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor

SFRP4+ cancer-associated fibroblasts drive IL-6/STAT3-mediated EMT and immunosuppressive tumor microenvironment in hepatocellular carcinoma (AACR 2026) - "Transcriptomic profiling of tumors from atezolizumab-bevacizumab (Atezo/Beva) responder and non-responder groups was further performed to assess clinical relevance. SFRP4⁺ CAFs exhibited an inflammatory phenotype characterized by marked induction of IL6 and NECTIN2 expression. SFRP4⁺ CAFs orchestrate a multifaceted pro-tumor program through IL6-STAT3/CD44 signaling, NECTIN-TIGIT-mediated Treg recruitment, and M2 macrophage polarization. High SFRP4 expression correlates with impaired cytotoxic immunity and poor response to Atezo/Beva therapy in HCC. Targeting SFRP4⁺ CAFs may represent a promising therapeutic strategy to overcome stromal-mediated immune resistance in liver cancer."

Biomarker • IO biomarker • Tumor microenvironment • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • CAFs • CD44 • CD8 • GZMA • IL6 • NECTIN2 • SFRP4 • STAT3 • TIGIT

Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial (IASLC-WCLC 2025) - P1, P3 | "Methods : Patients with ES-SCLC were eligible if they had completed 4 to 6 cycles of 1L platinum-etoposide chemotherapy and anti-PD-L1 (unless unavailable) without disease progression. Within 8 weeks from the start of the last chemo-immunotherapy cycle, patients received tarlatamab (10 mg IV Q2W) with either atezolizumab (1680 mg IV Q4W) or durvalumab (1500 mg IV Q4W) as 1L maintenance until disease progression...The median OS was 25.3 months (95% CI, 20.3-not reached) and the median PFS was 5.6 months (95% CI, 3.5-9.0) (Figure). Conclusions Tarlatamab in combination with anti-PD-L1 demonstrated an acceptable safety profile, with long-term tolerability and unprecedented OS."

Clinical • Lung Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3

Counterfeit cancer drugs: NAFDAC raises alarm over fake Avastin, Tecentriq (Vanguard Media Limited) - "Investigations revealed that the medicines were often sold at suspiciously lower prices, ranging between N180,000 and N350,000...NAFDAC identified specific counterfeit batches, including Avastin with batch numbers H4239A70, H2290A34, and A3508B02, as well as Tecentriq batch B3071A12...The agency said the counterfeit products showed multiple red flags: Batch numbers that do not exist in the manufacturer’s database, poor-quality printing and spelling errors, incorrect placement of information, tamper-evident labels inconsistent with genuine products and invalid serial numbers."

Commercial • Breast Cancer • Cervical Cancer • Colorectal Cancer • Glioblastoma • Hepatocellular Cancer • Melanoma • Non Small Cell Lung Cancer • Ovarian Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Urothelial Cancer

IMPRINTER: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: Imugene Limited | Active, not recruiting ➔ Terminated; Portfolio prioritization

Monotherapy • Trial termination • Large Cell Carcinoma • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-1 • PD-L1